<DOC>
	<DOCNO>NCT01004809</DOCNO>
	<brief_summary>Post-marketing surveillance ( PMS ) monitor safety effectiveness dutasteride Korean androgenetic alopecia patient</brief_summary>
	<brief_title>AVODARTÂ® Alopecia Post-marketing Surveillance ( PMS )</brief_title>
	<detailed_description>An open label , multi-centre , non-interventional post-marketing surveillance monitor safety effectiveness dutasteride administer Korean androgenetic alopecia patient accord prescribe information</detailed_description>
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Men ( 1841 year age ) male pattern hair loss ( androgenetic alopecia ) Subjects experience treatment use dutasteride Subjects investigator believe comply requirement protocol Subjects prescribe dutasteride accord Prescribing Information Considering nature observational study , GSK Korea encourage doctor participate study enrol subject prescribe dutasteride follow locally approve Prescribing Information . Subject give inform consent enrol . However , institution waif requirement inform consent , informed consent require . In case , monitor proceed .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>41 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Dutasteride</keyword>
</DOC>